Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 149Squamous Cell Carcinoma of Head and Neck 76Head and Neck Neoplasms 75Stomach Neoplasms 52Lung Neoplasms 52Esophageal Neoplasms 34Neoplasms 33Uterine Cervical Neoplasms 32Urinary Bladder Neoplasms 32Carcinoma, Squamous Cell 27Parkinson Disease 4, Autosomal Dominant Lewy Body 26Neoplasm Metastasis 26Small Cell Lung Carcinoma 23Breast Neoplasms 23Cholangiocarcinoma 21Carcinoma 19Ovarian Neoplasms 14Adenocarcinoma Of Esophagus 14Triple Negative Breast Neoplasms 13Pancreatic Neoplasms 13Oropharyngeal Neoplasms 13Mesothelioma, Malignant 13Adenocarcinoma 13Biliary Tract Neoplasms 12Mesothelioma 11Gallbladder Neoplasms 11Esophageal Squamous Cell Carcinoma 10Carcinoma, Transitional Cell 10Tongue Neoplasms 9Laryngeal Neoplasms 9

Interventions

trifluridine tipiracil drug combination 1tipiracil 1pembrolizumab 1cabozantinib 1andecaliximab 1Trifluridine 1S 1 (combination) 1Oxaliplatin 1Nivolumab 1Irinotecan 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastric Adenocarcinoma × Cisplatin × Clear all
NCT02862535 2020-12-24

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gilead Sciences

Phase 1 Terminated
36 enrolled 17 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡